We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

making it the fastest-growing biotech stock by retail engagement in this period. The rally follows PepGen's release of early clinical data from its FREEDOM-DM1 Phase 1 trial, evaluating PGN-EDODM1 ...

Assess today's live Plastic Additives JSC (PGN) share price, performance and insights using our live Hanoi: PGN stock exchange data. Analyse the historical data and Plastic Additives JSC share price ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

PGN-EDODM1 was observed to have a favorable emerging ... the FREEDOM2 5 mg/kg cohort in the first quarter of 2026. See what stocks are receiving strong buy ratings from top-rated analysts.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

spurring a significant stock drop. The Boston-based biotech said on Tuesday morning it would voluntarily pause a Phase 2 study of its drug, PGN-EDO51, in patients with Duchenne muscular dystrophy ...

Read Also: Streaming Stock’s Revenues Quadrupled ... PepGen says the company plans to advance PGN-EDODM1 into multiple-dose studies and expects additional results from the 15 mg/kg cohort ...

Company will temporarily pause CONNECT2 and focus efforts on ongoing CONNECT1-EDO51 study of PGN-EDO51 in DMD, with 10 mg/kg results expected in the third quarter of 2025 No new safety issues have ...